{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:52:13Z","timestamp":1780473133151,"version":"3.54.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.semarthrit.2012.03.004","type":"journal-article","created":{"date-parts":[[2012,4,17]],"date-time":"2012-04-17T01:22:27Z","timestamp":1334625747000},"page":"201-205","source":"Crossref","is-referenced-by-count":77,"title":["The Use of Canakinumab, a Novel IL-1\u03b2 Long-Acting Inhibitor, in Refractory Adult-Onset Still's Disease"],"prefix":"10.1016","volume":"42","author":[{"given":"Apostolos","family":"Kontzias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Efthimiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 48","key":"10.1016\/j.semarthrit.2012.03.004_bib1","first-page":"S53","article-title":"Autoinflammatory syndromes and infections: Pathogenetic and clinical implications","volume":"26","author":"Efthimiou","year":"2008","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2012.03.004_bib2","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/ncprheum0510","article-title":"Adult-onset Still's disease: Can recent advances in our understanding of its pathogenesis lead to targeted therapy?","volume":"3","author":"Efthimiou","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.03.004_bib3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2165\/00003495-200868030-00005","article-title":"Adult-onset Still's disease: Pathogenesis, clinical manifestations and therapeutic advances","volume":"68","author":"Kontzias","year":"2008","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.03.004_bib4","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s10067-011-1917-9","article-title":"Successful treatment of adult-onset Still's disease with tocilizumab monotherapy: Two case reports and literature review","volume":"31","author":"Sakai","year":"2012","journal-title":"Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2012.03.004_bib5","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1365-2125.2011.03958.x","article-title":"Rilonacept and canakinumab","volume":"71","author":"Dubois","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"23","key":"10.1016\/j.semarthrit.2012.03.004_bib6","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","article-title":"Use of canakinumab in the cryopyrin-associated periodic syndrome","volume":"360","author":"Lachmann","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.03.004_bib7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejim.2010.03.005","article-title":"Targeting IL-1beta in disease; the expanding role of NLRP3 inflammasome","volume":"21","author":"Mitroulis","year":"2010","journal-title":"Eur J Intern Med"},{"issue":"9","key":"10.1016\/j.semarthrit.2012.03.004_bib8","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s10067-010-1516-1","article-title":"Clinical features and prognosis in adult-onset Still's disease: A study of 104 cases","volume":"29","author":"Kong","year":"2010","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2012.03.004_bib9","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s00281-006-0015-6","article-title":"Hereditary auto-inflammatory disorders and biologics","volume":"27","author":"Church","year":"2006","journal-title":"Springer Semin Immunopathol"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.03.004_bib10","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.semarthrit.2007.04.002","article-title":"Anakinra in patients with treatment-resistant adult-onset Still's disease: Four case reports with serial cytokine measurements and a review of the literature","volume":"37","author":"K\u00f6tter","year":"2007","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.semarthrit.2012.03.004_bib11","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/art.21061","article-title":"Rapid responses to anakinra in patients with refractory adult-onset Still's disease","volume":"52","author":"Fitzgerald","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.03.004_bib12","first-page":"201","article-title":"Ferritin levels and response to treatment in patients with adult Still's disease","volume":"23","author":"Akritidis","year":"1996","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2012.03.004_bib13","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S1297-319X(02)00409-8","article-title":"Ferritin levels in adult Still's disease: Any sugar?","volume":"69","author":"Fautrel","year":"2002","journal-title":"Joint Bone Spine"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.03.004_bib14","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.2007.076034","article-title":"Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: Preliminary experience in France","volume":"67","author":"Lequerr\u00e9","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2012.03.004_bib15","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1358\/dot.2009.45.6.1378935","article-title":"Rilonacept in the treatment of chronic inflammatory disorders","volume":"45","author":"McDermott","year":"2009","journal-title":"Drugs Today (Barc) Rev"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.03.004_bib16","doi-asserted-by":"crossref","first-page":"R91","DOI":"10.1186\/ar3366","article-title":"Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: A case-series study","volume":"13","author":"Laskari","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.semarthrit.2012.03.004_bib17","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s10165-009-0254-1","article-title":"Marked effect and steroid-sparing ability of anakinra on a patient with refractory adult-onset Still's disease","volume":"20","author":"Tamaki","year":"2010","journal-title":"Mod Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2012.03.004_bib18","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1136\/ard.2009.108068","article-title":"IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease","volume":"69","author":"Naumann","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.semarthrit.2012.03.004_bib19","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1136\/ard.2004.026617","article-title":"Refractory adult onset Still's disease successfully treated with anakinra","volume":"64","author":"Vasques Godinho","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2012.03.004_bib20","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/art.33342","article-title":"A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features","volume":"64","author":"Ruperto","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.semarthrit.2012.03.004_bib21","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/art.30128","article-title":"Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: Report of forty-six patients from an international multicenter series","volume":"63","author":"Nigrovic","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.03.004_bib22","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1111\/j.1756-185X.2010.01474.x","article-title":"A case of refractory adult-onset Still's disease treated with anakinra","volume":"13","author":"Lahiri","year":"2010","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.03.004_bib23","first-page":"81","article-title":"Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders","volume":"11","author":"Church","year":"2009","journal-title":"Curr Opin Mol Ther"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.03.004_bib24","first-page":"138","article-title":"(Arcalyst), an interleukin-1 trap for the treatment of cryopyrin-associated periodic syndromes","volume":"34","author":"Kapur","year":"2009","journal-title":"Pt"},{"issue":"Suppl 3","key":"10.1016\/j.semarthrit.2012.03.004_bib25","article-title":"Successful use of the IL-1 trap rilonacept in adult-onset Still's disease refractory to anakinra [abstract]","volume":"70","author":"Petryna Olga","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.semarthrit.2012.03.004_bib26","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1084\/jem.20082481","article-title":"In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes","volume":"206","author":"Lachmann","year":"2009","journal-title":"J Exp Med"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017212000674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017212000674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,24]],"date-time":"2018-11-24T02:54:36Z","timestamp":1543028076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017212000674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0049017212000674"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2012.03.004","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}